Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution
BackgroundManaging the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.MethodsWe designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 day...
Main Authors: | Jesus Garcia-Donas, Diego Martínez-Urbistondo, Kyra Velázquez Kennedy, Paula Villares, Arántzazu Barquin, Andrea Dominguez, Juan Francisco Rodriguez-Moreno, Elena Caro, Rafael Suarez del Villar, Estanislao Nistal-Villan, Monica Yagüe, Maria Ortiz, Maria Barba, Sergio Ruiz-Llorente, Miguel Quiralte, Massimiliano Zanin, Cristina Rodríguez, Paloma Navarro, Pedro Berraondo, Rodrigo Madurga |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1156603/full |
Similar Items
-
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
by: Eylem Eliaçık, et al.
Published: (2015-05-01) -
Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review
by: Jona F. Houthuys, et al.
Published: (2022-12-01) -
Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations
by: Parvis Sadjadian, et al.
Published: (2020-10-01) -
Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
by: Owji S, et al.
Published: (2022-10-01) -
Efficacy of topical ruxolitinib for cutaneous dermatomyositis
by: Aviya Lanis, MD, et al.
Published: (2024-03-01)